Taipei, June 13, 2025 —
ImmunAdd Inc., a Taiwan-based biotech company, announced its participation in the 2025 BIO International Convention, taking place June 16–19 at the Boston Convention and Exhibition Center. The company will present its latest advancements in synthetic vaccine adjuvants and immune modulation technologies to the global biotech community.

At this year’s convention, ImmunAdd will spotlight its proprietary fully synthetic saponin adjuvant IA-05, alongside its IAS-01 adjuvant system, which combines IA-05 with a Toll-like receptor (TLR) agonist. The IAS-01 platform simultaneously activates both humoral and cellular immune responses, offering enhanced protection and longer-lasting durability for vaccine applications.

“Our participation in the BIO Convention marks an important milestone in our international outreach,” said by Dr. Pi-Hui Liang, the CEO of ImmunAdd. “As one of the most influential biotech gatherings in the world, this event offers us a valuable opportunity to share our innovation roadmap and engage with potential global partners and investors.”

The convention will also serve as a strategic platform for ImmunAdd to explore international collaborations and commercial partnerships. The company plans to engage with vaccine developers, biopharmaceutical companies, and research institutions to discuss opportunities in co-development, licensing, and investment.

ImmunAdd warmly invites industry partners to visit its booth to learn more about how its patented adjuvant technology is driving the future of vaccines and immunotherapies.

Exhibition Details:
BIO International Convention 2025
Location: Boston Convention and Exhibition Center, Boston, MA, USA
Dates: June 16–19, 2025
Booth: Taiwan Pavilion

Contact:
contact@immunadd.com